#BEGIN_DRUGCARD DB01373

# AHFS_Codes:
34:00.00
40:12.00
40:18.17
40:18.19
40:34.00*
56:04.00
56:12.00
88:08.00
88:12.00
88:29.00*
92:02.00*

# ATC_Codes:
A01AD11
A02AC01
A02AC02
A06AC08
A07XA03
A11GA01
A11HA31
A12AA01
A12AA02
A12AA03
A12AA04
A12AA05
A12AA06
A12AA07
A12AA08
A12AA09
A12AA10
A12AA11
A12AA12
A12AA20
A12AA30
B01AC08
B02BC08
B05XA07
C05BX01
D03AX04
D11AX03
G04BA03
J04AA03
N02BA15
N07BB02
R01AX01
V03AE01
V03AF03
V03AF04
V08AC10

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
22984

# Chemical_Formula:
Not Available

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2007-07-06 14:28:41 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium.  Low calcium intake may also be a risk factor in the development of osteoporosis.  The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast.

# Dosage_Forms:
Capsule	Oral
Liquid	Dental
Liquid	Intravenous
Liquid	Oral
Liquid	Sublingual
Paste	Dental
Powder	Oral
Powder, for solution	Oral
Solution	Intramuscular
Solution	Intravenous
Solution	Oral
Solution / drops	Oral
Syrup	Oral
Tablet	Oral
Tablet, chewable	Oral

# Drug_Category:
Not Available

# Drug_Interactions:
Alendronate	Formation of non-absorbable complexes
Amprenavir	The antiacid decreases the absorption of amprenavir
Atazanavir	This gastric pH modifier decreases the levels/effects of atazanavir
Chloroquine	The antiacid decreases the absorption of chloroquine
Ciprofloxacin	Formation of non-absorbable complexes
Clodronate	Formation of non-absorbable complexes
Dapsone	Formation of non-absorbable complexes
Deferiprone	Deferiprone serum concentrations may be decreased by calcium salts.
Delavirdine	The antiacid decreases the effect of delavirdine
Demeclocycline	Formation of non-absorbable complexes
Doxycycline	Formation of non-absorbable complexes
Enoxacin	Formation of non-absorbable complexes
Etidronic acid	Formation of non-absorbable complexes
Fosamprenavir	The antiacid decreases the absorption of amprenavir
Grepafloxacin	Calcium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours.
Ibandronate	Formation of non-absorbable complexes
Indinavir	Calcium may decrease the absorption of indinavir.
Itraconazole	Calcium-containing antacids may decrease the effect of itraconazole.
Ketoconazole	Calcium-containing antacids may decrease the absorption of ketoconazole.
Levofloxacin	Formation of non-absorbable complexes
Levothyroxine	Calcium decreases absorption of levothyroxine
Lomefloxacin	Formation of non-absorbable complexes
Methacycline	Formation of non-absorbable complexes
Minocycline	Formation of non-absorbable complexes
Moxifloxacin	Formation of non-absorbable complexes
Mycophenolate mofetil	Formation of non-absorbable complexes
Norfloxacin	Formation of non-absorbable complexes
Ofloxacin	Formation of non-absorbable complexes
Oxytetracycline	Formation of non-absorbable complexes
Pefloxacin	Formation of non-absorbable complexes
Polystyrene sulfonate	Formation of non-absorbable complexes
Risedronate	Formation of non-absorbable complexes
Temafloxacin	Formation of non-absorbable complexes
Tetracycline	Formation of non-absorbable complexes
Trovafloxacin	Formation of non-absorbable complexes

# Drug_Reference:
15860827	Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, Baverstock M, Birks Y, Dumville J, Francis R, Iglesias C, Puffer S, Sutcliffe A, Watt I, Torgerson DJ: Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ. 2005 Apr 30;330(7498):1003.
15885294	Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA: Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005 May 7-13;365(9471):1621-8.
16034903	Weingarten MA, Zalmanovici A, Yaphe J: Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003548.
16481635	Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D: Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006 Feb 16;354(7):669-83.
9278463	Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997 Sep 4;337(10):670-6.

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Calcium

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1373

# Mechanism_Of_Action:
Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. More than 500 human proteins are known to bind or transport calcium.   The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the free, ionized form or bound to blood proteins such as serum albumin. Parathyroid hormone (secreted from the parathyroid gland) regulates the resorption of Ca2+ from bone. Calcitonin stimulates incorporation of calcium in bone, although this process is largely independent of calcitonin. Although calcium flow to and from the bone is neutral, about 5 mmol is turned over a day. Bone serves as an important storage point for calcium, as it contains 99% of the total body calcium.  Low calcium intake may also be a risk factor in the development of osteoporosis.  The best-absorbed form of calcium from a pill is a calcium salt like carbonate or phosphate. Calcium gluconate and calcium lactate are absorbed well by pregnant women. Seniors absorb calcium lactate, gluconate and citrate better unless they take their calcium supplement with a full breakfast. The currently recommended calcium intake is 1,500 milligrams per day for women not taking estrogen and 800 milligrams per day for women on estrogen. There is close to 300 milligrams of calcium in one cup of fluid milk. Calcium carbonate is currently the best and least expensive form of calcium supplement available.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
Not Available

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448718

# Pharmacology:
Calcium (Ca2+) plays a pivotal role in the physiology and biochemistry of organisms and the cell. It plays an important role in signal transduction pathways, where it acts as a second messenger, in neurotransmitter release from neurons, contraction of all muscle cell types, and fertilization. Many enzymes require calcium ions as a cofactor, those of the blood-clotting cascade being notable examples. Extracellular calcium is also important for maintaining the potential difference across excitable cell membranes, as well as proper bone formation.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB01373

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2012-02-14 11:47:06 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Calcium

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
21303162	Boda D, Giri J, Henderson D, Eisenberg B, Gillespie D: Analyzing the components of the free-energy landscape in a calcium selective ion channel by Widom's particle insertion method. J Chem Phys. 2011 Feb 7;134(5):055102.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CACNA1C

# Drug_Target_1_GenBank_ID_Gene:
M92270

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
CACNA1C

# Drug_Target_1_Gene_Name:
CACNA1C

# Drug_Target_1_Gene_Sequence:
>6666 bp
ATGGTCAATGAGAATACGAGGATGTACATTCCAGAGGAAAACCACCAAGGTTCCAACTAT
GGGAGCCCACGCCCCGCCCATGCCAACATGAATGCCAATGCGGCAGCGGGGCTGGCCCCT
GAGCACATCCCCACCCCGGGGGCTGCCCTGTCGTGGCAGGCGGCCATCGACGCAGCCCGG
CAGGCTAAGCTGATGGGCAGCGCTGGCAATGCGACCATCTCCACAGTCAGCTCCACGCAG
CGGAAGCGGCAGCAATATGGGAAACCCAAGAAGCAGGGCAGCACCACGGCCACACGCCCG
CCCCGAGCCCTGCTCTGCCTGACCCTGAAGAACCCCATCCGGAGGGCCTGCATCAGCATT
GTCGAATGGAAACCATTTGAAATAATTATTTTACTGACTATTTTTGCCAATTGTGTGGCC
TTAGCGATCTATATTCCCTTTCCAGAAGATGATTCCAACGCCACCAATTCCAACCTGGAA
CGAGTGGAATATCTCTTTCTCATAATTTTTACGGTGGAAGCGTTTTTAAAAGTAATCGCC
TATGGACTCCTCTTTCACCCCAATGCCTACCTCCGCAACGGCTGGAACCTACTAGATTTT
ATAATTGTGGTTGTGGGGCTTTTTAGTGCAATTTTAGAACAAGCAACCAAAGCAGATGGG
GCAAACGCTCTCGGAGGGAAAGGGGCCGGATTTGATGTGAAGGCGCTGAGGGCCTTCCGC
GTGCTGCGCCCCCTGCGGCTGGTGTCCGGAGTCCCAAGTCTCCAGGTGGTCCTGAATTCC
ATCATCAAGGCCATGGTCCCCCTGCTGCACATCGCCCTGCTTGTGCTGTTTGTCATCATC
ATCTACGCCATCATCGGCTTGGAGCTCTTCATGGGGAAGATGCACAAGACCTGCTACAAC
CAGGAGGGCATAGCAGATGTTCCAGCAGAAGATGACCCTTCCCCTTGTGCGCTGGAAACG
GGCCACGGGCGGCAGTGCCAGAACGGCACGGTGTGCAAGCCCGGCTGGGATGGTCCCAAG
CACGGCATCACCAACTTTGACAACTTTGCCTTCGCCATGCTCACGGTGTTCCAGTGCATC
ACCATGGAGGGCTGGACGGACGTGCTGTACTGGGTCAATGATGCCGTAGGAAGGGACTGG
CCCTGGATCTATTTTGTTACACTAATCATCATAGGGTCATTTTTTGTACTTAACTTGGTT
CTCGGTGTGCTTAGCGGAGAGTTTTCCAAAGAGAGGGAGAAGGCCAAGGCCCGGGGAGAT
TTCCAGAAGCTGCGGGAGAAGCAGCAGCTAGAAGAGGATCTCAAAGGCTACCTGGATTGG
ATCACTCAGGCCGAAGACATCGATCCTGAGAATGAGGACGAAGGCATGGATGAGGAGAAG
CCCCGAAACATGAGCATGCCCACCAGTGAGACCGAGTCCGTCAACACCGAAAACGTGGCT
GGAGGTGACATCGAGGGAGAAAACTGCGGGGCCAGGCTGGCCCACCGGATCTCCAAGTCA
AAGTTCAGCCGCTACTGGCGCCGGTGGAATCGGTTCTGCAGAAGGAAGTGCCGCGCCGCA
GTCAAGTCTAATGTCTTCTACTGGCTGGTGATTTTCCTGGTGTTCCTCAACACGCTCACC
ATTGCCTCTGAGCACTACAACCAGCCCAACTGGCTCACAGAAGTCCAAGACACGGCAAAC
AAGGCCCTGCTGGCCCTGTTCACGGCAGAGATGCTCCTGAAGATGTACAGCCTGGGCCTG
CAGGCCTACTTCGTGTCCCTCTTCAACCGCTTTGACTGCTTCGTCGTGTGTGGCGGCATC
CTGGAGACCATCCTGGTGGAGACCAAGATCATGTCCCCACTGGGCATCTCCGTGCTCAGA
TGCGTCCGGCTGCTGAGGATTTTCAAGATCACGAGGTACTGGAACTCCTTGAGCAACCTG
GTGGCATCCTTGCTGAACTCTGTGCGCTCCATCGCCTCCCTGCTCCTTCTCCTCTTCCTC
TTCATCATCATCTTCTCCCTCCTGGGGATGCAGCTCTTTGGAGGAAAGTTCAACTTTGAT
GAGATGCAGACCCGGAGGAGCACATTCGATAACTTCCCCCAGTCCCTCCTCACTGTGTTT
CAGATCCTGACCGGGGAGGACTGGAATTCGGTGATGTATGATGGGATCATGGCTTATGGC
GGCCCCTCTTTTCCAGGGATGTTAGTCTGTATTTACTTCATCATCCTCTTCATCTGTGGA
AACTATATCCTACTGAATGTGTTCTTGGCCATTGCTGTGGACAACCTGGCTGATGCTGAG
AGCCTCACATCTGCCCAAAAGGAGGAGGAAGAGGAGAAGGAGAGAAAGAAGCTGGCCAGG
ACTGCCAGCCCAGAGAAGAAACAAGAGTTGGTGGAGAAGCCGGCAGTGGGGGAATCCAAG
GAGGAGAAGATTGAGCTGAAATCCATCACGGCTGACGGAGAGTCTCCACCCGCCACCAAG
ATCAACATGGATGACCTCCAGCCCAATGAAAATGAGGATAAGAGCCCCTACCCCAACCCA
GAAACTACAGGAGAAGAGGATGAGGAGGAGCCAGAGATGCCTGTCGGCCCTCGCCCACGA
CCACTCTCTGAGCTTCACCTTAAGGAAAAGGCAGTGCCCATGCCAGAAGCCAGCGCGTTT
TTCATCTTCAGCTCTAACAACAGGTTTCGCCTCCAGTGCCACCGCATTGTCAATGACACG
ATCTTCACCAACCTGATCCTCTTCTTCATTCTGCTCAGCAGCATTTCCCTGGCTGCTGAG
GACCCGGTCCAGCACACCTCCTTCAGGAACCATATTCTGTTTTATTTTGATATTGTTTTT
ACCACCATTTTCACCATTGAAATTGCTCTGAAGATCCTAGGCAATGCAGACTATGTCTTC
ACTAGTATCTTTACATTAGAAATTATCCTTAAGATGACTGCTTATGGGGCTTTCTTGCAC
AAGGGTTCTTTCTGCCGGAACTACTTCAACATCCTGGACCTGCTGGTGGTCAGCGTGTCC
CTCATCTCCTTTGGCATCCAGTCCAGTGCAATCAATGTCGTGAAGATCTTGCGAGTCCTG
CGAGTACTCAGGCCCCTGAGGGCCATCAACAGGGCCAAGGGGCTAAAGCATGTGGTTCAG
TGTGTGTTTGTCGCCATCCGGACCATCGGGAACATCGTGATTGTCACCACCCTGCTGCAG
TTCATGTTTGCCTGCATCGGGGTCCAGCTCTTCAAGGGAAAGCTGTACACCTGTTCAGAC
AGTTCCAAGCAGACAGAGGCGGAATGCAAGGGCAACTACATCACGTACAAAGACGGGGAG
GTTGACCACCCCATCATCCAACCCCGCAGCTGGGAGAACAGCAAGTTTGACTTTGACAAT
GTTCTGGCAGCCATGATGGCCCTCTTCACCGTCTCCACCTTCGAAGGGTGGCCAGAGCTG
CTGTACCGCTCCATCGACTCCCACACGGAAGACAAGGGCCCCATCTACAACTACCGTGTG
GAGATCTCCATCTTCTTCATCATCTACATCATCATCATCGCCTTCTTCATGATGAACATC
TTCGTGGGCTTCGTCATCGTCACCTTTCAGGAGCAGGGGGAGCAGGAGTACAAGAACTGT
GAGCTGGACAAGAACCAGCGACAGTGCGTGGAATACGCCCTCAAGGCCCGGCCCCTGCGG
AGGTACATCCCCAAGAACCAGCACCAGTACAAAGTGTGGTACGTGGTCAACTCCACCTAC
TTCGAGTACCTGATGTTCGTCCTCATCCTGCTCAACACCATCTGCCTGGCCATGCAGCAC
TACGGCCAGAGCTGCCTGTTCAAAATCGCCATGAACATCCTCAACATGCTCTTCACTGGC
CTCTTCACCGTGGAGATGATCCTGAAGCTCATTGCCTTCAAACCCAAGGGTTACTTTAGT
GATCCCTGGAATGTTTTTGACTTCCTCATCGTAATTGGCAGCATAATTGACGTCATTCTC
AGTGAGACTAATCACTATTTCTGTGATGCATGGAATACATTTGACGCCTTGATTGTTGTG
GGTAGCATTGTTGATATAGCAATCACCGAGGTAAACCCAGCTGAACATACCCAATGCTCT
CCCTCTATGAACGCAGAGGAAAACTCCCGCATCTCCATCACCTTCTTCCGCCTGTTCCGG
GTCATGCGTCTGGTGAAGCTGCTGAGCCGTGGGGAGGGCATCCGGACGCTGCTGTGGACC
TTCATCAAGTCCTTCCAGGCCCTGCCCTATGTGGCCCTCCTGATCGTGATGCTGTTCTTC
ATCTACGCGGTGATCGGGATGCAGGTGTTTGGGAAAATTGCCCTGAATGATACCACAGAG
ATCAACCGGAACAACAACTTTCAGACCTTCCCCCAGGCCGTGCTGCTCCTCTTCAGGTGT
GCCACCGGGGAGGCCTGGCAGGACATCATGCTGGCCTGCATGCCAGGCAAGAAGTGTGCC
CCAGAGTCCGAGCCCAGCAACAGCACGGAGGGTGAAACACCCTGTGGTAGCAGCTTTGCT
GTCTTCTACTTCATCAGCTTCTACATGCTCTGTGCCTTCCTGATCATCAACCTCTTTGTA
GCTGTCATCATGGACAACTTTGACTACCTGACAAGGGACTGGTCCATCCTTGGTCCCCAC
CACCTGGATGAGTTTAAAAGAATCTGGGCAGAGTATGACCCTGAAGCCAAGGGTCGTATC
AAACACCTGGATGTGGTGACCCTCCTCCGGCGGATTCAGCCGCCACTAGGTTTTGGGAAG
CTGTGCCCTCACCGCGTGGCTTGCAAACGCCTGGTCTCCATGAACATGCCTCTGAACAGC
GACGGGACAGTCATGTTCAATGCCACCCTGTTTGCCCTGGTCAGGACGGCCCTGAGGATC
AAAACAGAAGGGAACCTAGAACAAGCCAATGAGGAGCTGCGGGCGATCATCAAGAAGATC
TGGAAGCGGACCAGCATGAAGCTGCTGGACCAGGTGGTGCCCCCTGCAGGTGATGATGAG
GTCACCGTTGGCAAGTTCTACGCCACGTTCCTGATCCAGGAGTACTTCCGGAAGTTCAAG
AAGCGCAAAGAGCAGGGCCTTGTGGGCAAGCCCTCCCAGAGGAACGCGCTGTCTCTGCAG
GCTGGCTTGCGCACACTGCATGACATCGGGCCTGAGATCCGACGGGCCATCTCTGGAGAT
CTCACCGCTGAGGAGGAGCTGGACAAGGCCATGAAGGAGGCTGTGTCCGCTGCTTCTGAA
GATGACATCTTCAGGAGGGCCGGTGGCCTGTTCGGCAACCACGTCAGCTACTACCAAAGC
GACGGCCGGAGCGCCTTCCCCCAGACCTTCACCACTCAGCGCCCGCTGCACATCAACAAG
GCGGGCAGCAGCCAGGGCGACACTGAGTCGCCATCCCACGAGAAGCTGGTGGACTCCACC
TTCACCCCGAGCAGCTACTCGTCCACCGGCTCCAACGCCAACATCAACAACGCCAACAAC
ACCGCCCTGGGTCGCCTCCCTCGCCCCGCCGGCTACCCCAGCACGGTCAGCACTGTGGAG
GGCCACGGGCCCCCCTTGTCCCCTGCCATCCGGGTGCAGGAGGTGGCGTGGAAGCTCAGC
TCCAACAGGGAAAGGCACGTTCCGGTGTGTGAGGATCTGGAGCTCAGGAGGGATTCAGGC
TCAGCAGGGACTCAGGCTCACTGCCTTCTGCTCAGGAGAGCAAACCCCTCTAGGTGCCAC
TCCCGGGAGAGCCAGGCAGCCATGGCGGGTCAGGAGGAGACGTCTCAGGATGAGACCTAT
GAAGTGAAGATGAACCATGACACGGAGGCCTGCAGTGAGCCCAGCCTGCTCTCCACAGAG
ATGCTCTCCTACCAGGATGACGAAAATCGGCAACTGACGCTCCCAGAGGAGGACAAGAGG
GACATCCGGCAATCTCCGAAGAGGGGTTTCCTCCGCTCTGCCTCACTAGGTCGAAGGGCC
TCCTTCCACCTGGAATGTCTGAAGCGACAGAAGGACCGAGGGGGAGACATCTCTCAGAAG
ACAGTCCTGCCCTTGCATCTGGTTCATCATCAGGCATTGGCAGTGGCAGGCCTGAGCCCC
CTCCTCCAGAGAAGCCATTCCCCTGCCTCATTCCCTAGGCCTTTTGCCACCCCACCAGCC
ACACCTGGCAGCCGAGGCTGGCCCCCACAGCCCGTCCCCACCCTGCGGCTTGAGGGGGTC
GAGTCCAGTGAGAAACTCAACAGCAGCTTCCCATCCATCCACTGCGGCTCCTGGGCTGAG
ACCACCCCCGGTGGCGGGGGCAGCAGCGCCGCCCGGAGAGTCCGGCCCGTCTCCCTCATG
GTGCCCAGCCAGGCTGGGGCCCCAGGGAGGCAGTTCCACGGCAGTGCCAGCAGCCTGGTG
GAAGCGGTCTTGATTTCAGAAGGACTGGGGCAGTTTGCTCAAGATCCCAAGTTCATCGAG
GTCACCACCCAGGAGCTGGCCGACGCCTGCGACATGACCATAGAGGAGATGGAGAGCGCG
GCCGACAACATCCTCAGCGGGGGCGCCCCACAGAGCCCCAATGGCGCCCTCTTACCCTTT
GTGAACTGCAGGGACGCGGGGCAGGACCGAGCCGGGGGCGAAGAGGACGCGGGCTGTGTG
CGCGCGCGGGGTGGACCGAGTGAGGAGGAGCTCCAGGACAGCAGGGTCTACGTCAGCAGC
CTGTAG

# Drug_Target_1_General_Function:
Involved in voltage-gated calcium channel activity

# Drug_Target_1_General_References:
1316612	Soldatov NM: Molecular diversity of L-type Ca2+ channel transcripts in human fibroblasts. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4628-32.
1335957	Sun W, McPherson JD, Hoang DQ, Wasmuth JJ, Evans GA, Montal M: Mapping of a human brain voltage-gated calcium channel to human chromosome 12p13-pter. Genomics. 1992 Dec;14(4):1092-4.
1653763	Powers PA, Gregg RG, Lalley PA, Liao M, Hogan K: Assignment of the human gene for the alpha 1 subunit of the cardiac DHP-sensitive Ca2+ channel (CCHL1A1) to chromosome 12p12-pter. Genomics. 1991 Jul;10(3):835-9.
2173707	Perez-Reyes E, Wei XY, Castellano A, Birnbaumer L: Molecular diversity of L-type calcium channels. Evidence for alternative splicing of the transcripts of three non-allelic genes. J Biol Chem. 1990 Nov 25;265(33):20430-6.
7737988	Soldatov NM, Bouron A, Reuter H: Different voltage-dependent inhibition by dihydropyridines of human Ca2+ channel splice variants. J Biol Chem. 1995 May 5;270(18):10540-3.
7959794	Soldatov NM: Genomic structure of human L-type Ca2+ channel. Genomics. 1994 Jul 1;22(1):77-87.
8099908	Tang S, Mikala G, Bahinski A, Yatani A, Varadi G, Schwartz A: Molecular localization of ion selectivity sites within the pore of a human L-type cardiac calcium channel. J Biol Chem. 1993 Jun 25;268(18):13026-9.
8392192	Schultz D, Mikala G, Yatani A, Engle DB, Iles DE, Segers B, Sinke RJ, Weghuis DO, Klockner U, Wakamori M, et al.: Cloning, chromosomal localization, and functional expression of the alpha 1 subunit of the L-type voltage-dependent calcium channel from normal human heart. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6228-32.
9013606	Soldatov NM, Zuhlke RD, Bouron A, Reuter H: Molecular structures involved in L-type calcium channel inactivation. Role of the carboxyl-terminal region encoded by exons 40-42 in alpha1C subunit in the kinetics and Ca2+ dependence of inactivation. J Biol Chem. 1997 Feb 7;272(6):3560-6.
9087614	Klockner U, Mikala G, Eisfeld J, Iles DE, Strobeck M, Mershon JL, Schwartz A, Varadi G: Properties of three COOH-terminal splice variants of a human cardiac L-type Ca2+-channel alpha1-subunit. Am J Physiol. 1997 Mar;272(3 Pt 2):H1372-81.

# Drug_Target_1_HGNC_ID:
HGNC:1390

# Drug_Target_1_HPRD_ID:
00246

# Drug_Target_1_ID:
478

# Drug_Target_1_Locus:
12p13.3

# Drug_Target_1_Molecular_Weight:
248890

# Drug_Target_1_Name:
Voltage-dependent L-type calcium channel subunit alpha-1C

# Drug_Target_1_Number_of_Residues:
2221

# Drug_Target_1_PDB_ID:
1VYT

# Drug_Target_1_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Amlodipine Pathway	SMP00376
Atenolol Pathway	SMP00298
Benazepril Pathway	SMP00145
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Esmolol Pathway	SMP00301
Felodipine Pathway	SMP00377
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lisinopril Pathway	SMP00150
Metoprolol Pathway	SMP00302
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Nicotine Pathway	SMP00431
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Pindolol Pathway	SMP00306
Procainamide (Antiarrhythmic) Pathway	SMP00324
Propranolol Pathway	SMP00307
Quinapril Pathway	SMP00153
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Tocainide Pathway	SMP00330
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_1_Pfam_Domain_Function:
PF00520	Ion_trans

# Drug_Target_1_Protein_Sequence:
>Voltage-dependent L-type calcium channel subunit alpha-1C
MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAAR
QAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISI
VEWKPFEIIILLTIFANCVALAIYIPFPEDDSNATNSNLERVEYLFLIIFTVEAFLKVIA
YGLLFHPNAYLRNGWNLLDFIIVVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFR
VLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFMGKMHKTCYN
QEGIADVPAEDDPSPCALETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCI
TMEGWTDVLYWVNDAVGRDWPWIYFVTLIIIGSFFVLNLVLGVLSGEFSKEREKAKARGD
FQKLREKQQLEEDLKGYLDWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVA
GGDIEGENCGARLAHRISKSKFSRYWRRWNRFCRRKCRAAVKSNVFYWLVIFLVFLNTLT
IASEHYNQPNWLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGI
LETILVETKIMSPLGISVLRCVRLLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFL
FIIIFSLLGMQLFGGKFNFDEMQTRRSTFDNFPQSLLTVFQILTGEDWNSVMYDGIMAYG
GPSFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLADAESLTSAQKEEEEEKERKKLAR
TASPEKKQELVEKPAVGESKEEKIELKSITADGESPPATKINMDDLQPNENEDKSPYPNP
ETTGEEDEEEPEMPVGPRPRPLSELHLKEKAVPMPEASAFFIFSSNNRFRLQCHRIVNDT
IFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEIALKILGNADYVF
TSIFTLEIILKMTAYGAFLHKGSFCRNYFNILDLLVVSVSLISFGIQSSAINVVKILRVL
RVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSD
SSKQTEAECKGNYITYKDGEVDHPIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPEL
LYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVTFQEQGEQEYKNC
ELDKNQRQCVEYALKARPLRRYIPKNQHQYKVWYVVNSTYFEYLMFVLILLNTICLAMQH
YGQSCLFKIAMNILNMLFTGLFTVEMILKLIAFKPKGYFSDPWNVFDFLIVIGSIIDVIL
SETNHYFCDAWNTFDALIVVGSIVDIAITEVNPAEHTQCSPSMNAEENSRISITFFRLFR
VMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTE
INRNNNFQTFPQAVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFA
VFYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRI
KHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFALVRTALRI
KTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYATFLIQEYFRKFK
KRKEQGLVGKPSQRNALSLQAGLRTLHDIGPEIRRAISGDLTAEEELDKAMKEAVSAASE
DDIFRRAGGLFGNHVSYYQSDGRSAFPQTFTTQRPLHINKAGSSQGDTESPSHEKLVDST
FTPSSYSSTGSNANINNANNTALGRLPRPAGYPSTVSTVEGHGPPLSPAIRVQEVAWKLS
SNRERHVPVCEDLELRRDSGSAGTQAHCLLLRRANPSRCHSRESQAAMAGQEETSQDETY
EVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLGRRA
SFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPA
TPGSRGWPPQPVPTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLM
VPSQAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESA
ADNILSGGAPQSPNGALLPFVNCRDAGQDRAGGEEDAGCVRARGAPSEEELQDSRVYVSS
L

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the "high-voltage activated" (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin- GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Calcium channels containing the alpha-1C subunit play an important role in excitation-contraction coupling in the heart. The various isoforms display marked differences in the sensitivity to DHP compounds

# Drug_Target_1_SwissProt_ID:
Q13936

# Drug_Target_1_SwissProt_Name:
CAC1C_HUMAN

# Drug_Target_1_Synonyms:
Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle
Voltage- gated calcium channel subunit alpha Cav1.2

# Drug_Target_1_Theoretical_pI:
6.70

# Drug_Target_1_Transmembrane_Regions:
125-143
161-181
194-212
233-251
271-290
381-405
525-543
559-578
587-605
616-634
654-673
729-753
901-919
936-955
988-1006
1014-1032
1052-1071
1162-1186
1240-1258
1274-1293
1302-1320
1373-1391
1411-1430
1500-1524

# Drug_Target_2_Cellular_Location:
Golgi apparatus
Golgi apparatus membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
20573858	Bonza MC, Martin H, Kang M, Lewis G, Greiner T, Giacometti S, Van Etten JL, De Michelis MI, Thiel G, Moroni A: A functional calcium-transporting ATPase encoded by chlorella viruses. J Gen Virol. 2010 Oct;91(Pt 10):2620-9. Epub 2010 Jun 23.
9787799	Shi X, Chen M, Huvos PE, Hardwicke PM: Amino acid sequence of a Ca(2+)-transporting ATPase from the sarcoplasmic reticulum of the cross-striated part of the adductor muscle of the deep sea scallop: comparison to serca enzymes of other animals. Comp Biochem Physiol B Biochem Mol Biol. 1998 Jun;120(2):359-74.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
ATP2C1

# Drug_Target_2_GenBank_ID_Gene:
AF181120

# Drug_Target_2_GenBank_ID_Protein:
6715131

# Drug_Target_2_GeneCard_ID:
ATP2C1

# Drug_Target_2_Gene_Name:
ATP2C1

# Drug_Target_2_Gene_Sequence:
>2760 bp
ATGAAGGTTGCACGTTTTCAAAAAATACCTAATGGTGAAAATGAGACAATGATTCCTGTA
TTGACATCAAAAAAAGCAAGTGAATTACCAGTCAGTGAAGTTGCAAGCATTCTCCAAGCT
GATCTTCAGAATGGTCTAAACAAATGTGAAGTTAGTCATAGGCGAGCCTTTCATGGCTGG
AATAAGTTTGATATTAGTGAAGATGAGCCACTGTGGAAGAAGTATATTTCTCAGTTTAAA
AATCCCCTTATTATGCTGCTTCTGGCTTCTGCAGTCATCAGTGTTTTAATGCATCAGTTT
GATGATGCCGTCAGTATCACTGTGGCAATACTTATCGTTGTTACAGTTGCCTTTGTTCAG
GAATATCGTTCAGAAAAATCTCTTGAAGAATTGAGTAAACTTGTGCCACCAGAATGCCAT
TGTGTGCGTGAAGGAAAATTGGAGCATACACTTGCCCGAGACTTGGTTCCAGGTGATACA
GTTTGCCTTTCTGTTGGGGATAGAGTTCCTGCTGACTTACGCTTGTTTGAGGCTGTGGAT
CTTTCCATTGATGAGTCCAGCTTGACAGGTGAGACAACGCCTTGTTCTAAGGTGACAGCT
CCTCAGCCAGCTGCAACTAATGGAGATCTTGCATCGAGAAGTAACATTGCCTTTATGGGA
ACACTGGTCAGATGTGGCAAAGCAAAGGGTGTTGTCATTGGAACAGGAGAAAATTCTGAA
TTTGGGGAGGTTTTTAAAATGATGCAAGCAGAAGAGGCACCAAAAACCCCTCTGCAGAAG
AGCATGGACCTCTTAGGAAAACAACTTTCCTTTTACTCCTTTGGTATAATAGGAATCATC
ATGTTGGTTGGCTGGTTACTGGGAAAAGATATCCTGGAAATGTTTACTATTAGTGTAAGT
TTGGCTGTAGCAGCAATTCCTGAAGGTCTCCCCATTGTGGTCACAGTGACGCTAGCTCTT
GGTGTTATGAGAATGGTGAAGAAAAGGGCCATTGTGAAAAAGCTGCCTATTGTTGAAACT
CTGGGCTGCTGTAATGTGATTTGTTCAGATAAAACTGGAACACTGACGAAGAATGAAATG
ACTGTTACTCACATATTTACTTCAGATGGTCTGCATACTGAGGTTACTGGAGTTGGCTAT
AATCAATTTGGGGAAGTGATTGTTGATGGTGATGTTGTTCATGGATTCTATAACCCAGCT
GTTAGCAGAATTGTTGAGGCGGGCTGTGTGTGCAATGATGCTGTAATTAGAAACAATACT
CTAATGGGGAAGCCAACAGAAGGGGCCTTAATTGCTCTTGCAATGAAGATGGGTCTTGAT
GGACTTCAACAAGACTACATCAGAAAAGCTGAATACCCTTTTAGCTCTGAGCAAAAGTGG
ATGGCTGTTAAGTGTGTACACCGAACACAGCAGGACAGACCAGAGATTTGTTTTATGAAA
GGTGCTTACGAACAAGTAATTAAGTACTGTACTACATACCAGAGCAAAGGGCAGACCTTG
ACACTTACTCAGCAGCAGAGAGATGTGTACCAACAAGAGAAGGCACGCATGGGCTCAGCG
GGACTCAGAGTTCTTGCTTTGGCTTCTGGTCCTGAACTGGGACAGCTGACATTTCTTGGC
TTGGTGGGAATCATTGATCCACCTAGAACTGGTGTGAAAGAAGCTGTTACAACACTCATT
GCCTCAGGAGTATCAATAAAAATGATTACTGGAGATTCACAGGAGACTGCAGTTGCAATC
GCCAGTCGTCTGGGATTGTATTCCAAAACTTCCCAGTCAGTCTCAGGAGAAGAAATAGAT
GCAATGGATGTTCAGCAGCTTTCACAAATAGTACCAAAGGTTGCAGTATTTTACAGAGCT
AGCCCAAGGCACAAGATGAAAATTATTAAGTCGCTACAGAAGAACGGTTCAGTTGTAGCC
ATGACAGGAGATGGAGTAAATGATGCAGTTGCTCTGAAGGCTGCAGACATTGGAGTTGCG
ATGGGCCAGACTGGTACAGATGTTTGCAAAGAGGCAGCAGACATGATCCTAGTGGATGAT
GATTTTCAAACCATAATGTCTGCAATCGAAGAGGGTAAAGGGATTTATAATAACATTAAA
AATTTCGTTAGATTCCAGCTGAGCACGAGTATAGCAGCATTAACTTTAATCTCATTGGCT
ACATTAATGAACTTTCCTAATCCTCTCAATGCCATGCAGATTTTGTGGATCAATATTATT
ATGGATGGACCCCCAGCTCAGAGCCTTGGAGTAGAACCAGTGGATAAAGATGTCATTCGT
AAACCTCCTCGCAACTGGAAAGACAGCATTTTGACTAAAAACTTGATACTTAAAATACTT
GTTTCATCAATAATCATTGTTTGTGGGACTTTGTTTGTCTTCTGGCGTGAGCTACGAGAC
AATGTGATTACACCTCGAGACACAACAATGACCTTCACATGCTTTGTGTTTTTTGACATG
TTCAATGCACTAAGTTCCAGATCCCAGACCAAGTCTGTGTTTGAGATTGGACTCTGCAGT
AATAGAATGTTTTGCTATGCAGTTCTTGGATCCATCATGGGACAATTACTAGTTATTTAC
TTTCCTCCGCTTCAGAAGGTTTTTCAGACTGAGAGCCTAAGCATACTGGATCTGTTGTTT
CTTTTGGGTCTCACCTCATCAGTGTGCATAGTGGCAGAAATTATAAAGAAGGTTGAAAGG
AGCAGGGAAAAGATCCAGAAGCATGTTAGTTCGACATCATCATCTTTTCTTGAAGTATGA

# Drug_Target_2_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_2_General_References:
10615129	Hu Z, Bonifas JM, Beech J, Bench G, Shigihara T, Ogawa H, Ikeda S, Mauro T, Epstein EH Jr: Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet. 2000 Jan;24(1):61-5.
10718198	Nagase T, Kikuno R, Ishikawa KI, Hirosawa M, Ohara O: Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 2000 Feb 28;7(1):65-73.
10767338	Sudbrak R, Brown J, Dobson-Stone C, Carter S, Ramser J, White J, Healy E, Dissanayake M, Larregue M, Perrussel M, Lehrach H, Munro CS, Strachan T, Burge S, Hovnanian A, Monaco AP: Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca(2+) pump. Hum Mol Genet. 2000 Apr 12;9(7):1131-40.
11124703	Stanchi F, Bertocco E, Toppo S, Dioguardi R, Simionati B, Cannata N, Zimbello R, Lanfranchi G, Valle G: Characterization of 16 novel human genes showing high similarity to yeast sequences. Yeast. 2001 Jan 15;18(1):69-80.
12707275	Fairclough RJ, Dode L, Vanoevelen J, Andersen JP, Missiaen L, Raeymaekers L, Wuytack F, Hovnanian A: Effect of Hailey-Hailey Disease mutations on the function of a new variant of human secretory pathway Ca2+/Mn2+-ATPase (hSPCA1). J Biol Chem. 2003 Jul 4;278(27):24721-30. Epub 2003 Apr 21.

# Drug_Target_2_HGNC_ID:
HGNC:13211

# Drug_Target_2_HPRD_ID:
05089

# Drug_Target_2_ID:
241

# Drug_Target_2_Locus:
3q22.1

# Drug_Target_2_Molecular_Weight:
100579

# Drug_Target_2_Name:
Calcium-transporting ATPase type 2C member 1

# Drug_Target_2_Number_of_Residues:
919

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00122	E1-E2_ATPase
PF00689	Cation_ATPase_C
PF00690	Cation_ATPase_N
PF00702	Hydrolase

# Drug_Target_2_Protein_Sequence:
>Calcium-transporting ATPase type 2C member 1
MKVARFQKIPNGENETMIPVLTSKKASELPVSEVASILQADLQNGLNKCEVSHRRAFHGW
NEFDISEDEPLWKKYISQFKNPLIMLLLASAVISVLMHQFDDAVSITVAILIVVTVAFVQ
EYRSEKSLEELSKLVPPECHCVREGKLEHTLARDLVPGDTVCLSVGDRVPADLRLFEAVD
LSIDESSLTGETTPCSKVTAPQPAATNGDLASRSNIAFMGTLVRCGKAKGVVIGTGENSE
FGEVFKMMQAEEAPKTPLQKSMDLLGKQLSFYSFGIIGIIMLVGWLLGKDILEMFTISVS
LAVAAIPEGLPIVVTVTLALGVMRMVKKRAIVKKLPIVETLGCCNVICSDKTGTLTKNEM
TVTHIFTSDGLHAEVTGVGYNQFGEVIVDGDVVHGFYNPAVSRIVEAGCVCNDAVIRNNT
LMGKPTEGALIALAMKMGLDGLQQDYIRKAEYPFSSEQKWMAVKCVHRTQQDRPEICFMK
GAYEQVIKYCTTYQSKGQTLTLTQQQRDVYQQEKARMGSAGLRVLALASGPELGQLTFLG
LVGIIDPPRTGVKEAVTTLIASGVSIKMITGDSQETAVAIASRLGLYSKTSQSVSGEEID
AMDVQQLSQIVPKVAVFYRASPRHKMKIIKSLQKNGSVVAMTGDGVNDAVALKAADIGVA
MGQTGTDVCKEAADMILVDDDFQTIMSAIEEGKGIYNNIKNFVRFQLSTSIAALTLISLA
TLMNFPNPLNAMQILWINIIMDGPPAQSLGVEPVDKDVIRKPPRNWKDSILTKNLILKIL
VSSIIIVCGTLFVFWRELRDNVITPRDTTMTFTCFVFFDMFNALSSRSQTKSVFEIGLCS
NRMFCYAVLGSIMGQLLVIYFPPLQKVFQTESLSILDLLFLLGLTSSVCIVAEIIKKVER
SREKIQKHVSSTSSSFLEV

# Drug_Target_2_Reaction:
ATP + H2O + Ca2+cis = ADP + phosphate + Ca2+trans

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium

# Drug_Target_2_SwissProt_ID:
P98194

# Drug_Target_2_SwissProt_Name:
AT2C1_HUMAN

# Drug_Target_2_Synonyms:
ATP-dependent Ca(2+
ATPase 2C1
EC 3.6.3.8

# Drug_Target_2_Theoretical_pI:
6.72

# Drug_Target_2_Transmembrane_Regions:
71-91
105-123
263-282
295-312
700-719
730-750
771-793
809-828
842-860
876-896

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
2

# Drug_Target_3_Drug_References:
20371872	Dweck D, Reynaldo DP, Pinto JR, Potter JD: A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding. J Biol Chem. 2010 Jun 4;285(23):17371-9. Epub 2010 Apr 6.
20801130	Robertson IM, Sun YB, Li MX, Sykes BD: A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex. J Mol Cell Cardiol. 2010 Dec;49(6):1031-41. Epub 2010 Aug 27.
21035455	Kreutziger KL, Piroddi N, McMichael JT, Tesi C, Poggesi C, Regnier M: Calcium binding kinetics of troponin C strongly modulate cooperative activation and tension kinetics in cardiac muscle. J Mol Cell Cardiol. 2011 Jan;50(1):165-74. Epub 2010 Oct 28.
21250664	Martin SR, Avella G, Adrover M, de Nicola GF, Bullard B, Pastore A: Binding Properties of the Calcium-Activated F2 Isoform of Lethocerus Troponin C. Biochemistry. 2011 Feb 10.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X07898

# Drug_Target_3_GenBank_ID_Protein:
36729

# Drug_Target_3_GeneCard_ID:
TNNC2

# Drug_Target_3_Gene_Name:
TNNC2

# Drug_Target_3_Gene_Sequence:
>483 bp
ATGACGGACCAGCAGGCTGAGGCCAGGTCCTACCTCAGCGAAGAGATGATCGCTGAGTTC
AAGGCTGCCTTTGACATGTTTGATGCTGATGGTGGTGGGGACATCAGCGTCAAGGAGTTG
GGCACGGTGATGAGGATGCTGGGCCAGACACCCACCAAGGAGGAGCTGGACGCCATCATC
GAGGAGGTGGATGAGGACGGCAGCGGCACCATCGACTTCGAGGAGTTCTTGGTCATGATG
GTGCGCCAGATGAAAGAGGACGCGAAAGGGAAGAGCGAGGAGGAGCTGGCCGAGTGCTTC
CGCATCTTCGACAGGAATGCAGACGGCTACATCGACCCGGAGGAGCTGGCTGAGATTTTC
AGGGCCTCCGGGGAGCACGTGACTGACGAGGAGATCGAATCTCTGATGAAAGACGGCGAC
AAGAACAACGACGGCCGCATTGACTTCGACGAGTTCCTGAAGATGATGGAGGGCGTGCAG
TAA

# Drug_Target_3_General_Function:
Involved in calcium ion binding

# Drug_Target_3_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
2373703	Gahlmann R, Kedes L: Cloning, structural analysis, and expression of the human fast twitch skeletal muscle troponin C gene. J Biol Chem. 1990 Jul 25;265(21):12520-8.
3166492	Gahlmann R, Wade R, Gunning P, Kedes L: Differential expression of slow and fast skeletal muscle troponin C. Slow skeletal muscle troponin C is expressed in human fibroblasts. J Mol Biol. 1988 May 20;201(2):379-91.
978749	Romero-Herrera AE, Castillo O, Lehmann H: Human skeletal muscle proteins. The primary structure of troponin C. J Mol Evol. 1976 Oct 27;8(3):251-70.

# Drug_Target_3_HGNC_ID:
GNC:11944

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6048

# Drug_Target_3_Locus:
20q12-q13.11

# Drug_Target_3_Molecular_Weight:
18121.9

# Drug_Target_3_Name:
Troponin C, skeletal muscle

# Drug_Target_3_Number_of_Residues:
160

# Drug_Target_3_PDB_ID:
1A2X

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00036	efhand

# Drug_Target_3_Protein_Sequence:
>Troponin C, skeletal muscle
MTDQQAEARSYLSEEMIAEFKAAFDMFDADGGGDISVKELGTVMRMLGQTPTKEELDAII
EEVDEDGSGTIDFEEFLVMMVRQMKEDAKGKSEEELAECFRIFDRNADGYIDPEELAEIF
RASGEHVTDEEIESLMKDGDKNNDGRIDFDEFLKMMEGVQ

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components:Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments

# Drug_Target_3_SwissProt_ID:
P02585

# Drug_Target_3_SwissProt_Name:
TNNC2_HUMAN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
3.81

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
20371872	Dweck D, Reynaldo DP, Pinto JR, Potter JD: A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding. J Biol Chem. 2010 Jun 4;285(23):17371-9. Epub 2010 Apr 6.
20459070	Swindle N, Tikunova SB: Hypertrophic cardiomyopathy-linked mutation D145E drastically alters calcium binding by the C-domain of cardiac troponin C. Biochemistry. 2010 Jun 15;49(23):4813-20.
20566645	Parvatiyar MS, Pinto JR, Liang J, Potter JD: Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. J Biol Chem. 2010 Sep 3;285(36):27785-97. Epub 2010 Jun 21.
20599552	Baylor SM, Hollingworth S: Calcium indicators and calcium signalling in skeletal muscle fibres during excitation-contraction coupling. Prog Biophys Mol Biol. 2010 Jun 25.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
TNNC1

# Drug_Target_4_GenBank_ID_Gene:
X07897

# Drug_Target_4_GenBank_ID_Protein:
37208

# Drug_Target_4_GeneCard_ID:
TNNC1

# Drug_Target_4_Gene_Name:
TNNC1

# Drug_Target_4_Gene_Sequence:
>486 bp
ATGGATGACATCTACAAGGCTGCGGTAGAGCAGCTGACAGAAGAGCAGAAAAATGAGTTC
AAGGCAGCCTTCGACATCTTCGTGCTGGGCGCTGAGGATGGCTGCATCAGCACCAAGGAG
CTGGGCAAGGTGATGAGGATGCTGGGCCAGAACCCCACCCCTGAGGAGCTGCAGGAGATG
ATCGATGAGGTGGACGAGGACGGCAGCGGCACGGTGGACTTTGATGAGTTCCTGGTCATG
ATGGTTCGGTGCATGAAGGACGACAGCAAAGGGAAATCTGAGGAGGAGCTGTCTGACCTC
TTCCGCATGTTTGACAAAAATGCTGATGGCTACATCGACCTGGATGAGCTGAAGATAATG
CTGCAGGCTACAGGCGAGACCATCACGGAGGACGACATCGAGGAGCTCATGAAGGACGGA
GACAAGAACAACGACGGCCGCATCGACTATGATGAGTTCCTGGAGTTCATGAAGGGTGTG
GAGTAG

# Drug_Target_4_General_Function:
Involved in calcium ion binding

# Drug_Target_4_General_References:
2250022	Schreier T, Kedes L, Gahlmann R: Cloning, structural analysis, and expression of the human slow twitch skeletal muscle/cardiac troponin C gene. J Biol Chem. 1990 Dec 5;265(34):21247-53.
3166492	Gahlmann R, Wade R, Gunning P, Kedes L: Differential expression of slow and fast skeletal muscle troponin C. Slow skeletal muscle troponin C is expressed in human fibroblasts. J Mol Biol. 1988 May 20;201(2):379-91.
3951483	Roher A, Lieska N, Spitz W: The amino acid sequence of human cardiac troponin-C. Muscle Nerve. 1986 Jan;9(1):73-7.
9315850	Spyracopoulos L, Li MX, Sia SK, Gagne SM, Chandra M, Solaro RJ, Sykes BD: Calcium-induced structural transition in the regulatory domain of human cardiac troponin C. Biochemistry. 1997 Oct 7;36(40):12138-46.

# Drug_Target_4_HGNC_ID:
HGNC:11943

# Drug_Target_4_HPRD_ID:
08930

# Drug_Target_4_ID:
1561

# Drug_Target_4_Locus:
3p21.3-p14.3

# Drug_Target_4_Molecular_Weight:
18403

# Drug_Target_4_Name:
Troponin C, slow skeletal and cardiac muscles

# Drug_Target_4_Number_of_Residues:
161

# Drug_Target_4_PDB_ID:
1LA0

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00036	efhand

# Drug_Target_4_Protein_Sequence:
>Troponin C, slow skeletal and cardiac muscles
MDDIYKAAVEQLTEEQKNEFKAAFDIFVLGAEDGCISTKELGKVMRMLGQNPTPEELQEM
IDEVDEDGSGTVDFDEFLVMMVRCMKDDSKGKSEEELSDLFRMFDKNADGYIDLDELKIM
LQATGETITEDDIEELMKDGDKNNDGRIDYDEFLEFMKGVE

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components:Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments

# Drug_Target_4_SwissProt_ID:
P63316

# Drug_Target_4_SwissProt_Name:
TNNC1_HUMAN

# Drug_Target_4_Synonyms:
TN-C

# Drug_Target_4_Theoretical_pI:
3.78

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
1537825	Wallis CJ, Wenegieme EF, Babitch JA: Characterization of calcium binding to brain spectrin. J Biol Chem. 1992 Mar 5;267(7):4333-7.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
Not Available

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
SPTBN1

# Drug_Target_5_Gene_Sequence:
Not Available

# Drug_Target_5_General_Function:
Not Available

# Drug_Target_5_General_References:
Not Available

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
7103

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
Not Available

# Drug_Target_5_Name:
Spectrin beta chain, brain 1

# Drug_Target_5_Number_of_Residues:
0

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
Not Available

# Drug_Target_5_Protein_Sequence:
Not Available

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
Not Available

# Drug_Target_5_Specific_Function:
Not Available

# Drug_Target_5_SwissProt_ID:
Q01082

# Drug_Target_5_SwissProt_Name:
SPTB2_HUMAN

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
Not Available

# Drug_Target_5_Transmembrane_Regions:
Not Available

# Drug_Target_6_Cellular_Location:
Cytoplasm. Nucleus

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17515952	Lee TS, Mane S, Eid T, Zhao H, Lin A, Guan Z, Kim JH, Schweitzer J, King-Stevens D, Weber P, Spencer SS, Spencer DD, de Lanerolle NC: Gene expression in temporal lobe epilepsy is consistent with increased release of glutamate by astrocytes. Mol Med. 2007 Jan-Feb;13(1-2):1-13.
17536784	Marlatt NM, Shaw GS: Amide exchange shows calcium-induced conformational changes are transmitted to the dimer interface of S100B. Biochemistry. 2007 Jun 26;46(25):7478-87. Epub 2007 May 31.
17612632	Liang J, Luo G, Ning X, Shi Y, Zhai H, Sun S, Jin H, Liu Z, Zhang F, Lu Y, Zhao Y, Chen X, Zhang H, Guo X, Wu K, Fan D: Differential expression of calcium-related genes in gastric cancer cells transfected with cellular prion protein. Biochem Cell Biol. 2007 Jun;85(3):375-83.
17624933	Friel LA, Romero R, Edwin S, Nien JK, Gomez R, Chaiworapongsa T, Kusanovic JP, Tolosa JE, Hassan SS, Espinoza J: The calcium binding protein, S100B, is increased in the amniotic fluid of women with intra-amniotic infection/inflammation and preterm labor with intact or ruptured membranes. J Perinat Med. 2007;35(5):385-93.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
S100B

# Drug_Target_6_GenBank_ID_Gene:
M59488

# Drug_Target_6_GenBank_ID_Protein:
337730

# Drug_Target_6_GeneCard_ID:
S100B

# Drug_Target_6_Gene_Name:
S100B

# Drug_Target_6_Gene_Sequence:
>279 bp
ATGTCTGAGCTGGAGAAGGCCATGGTGGCCCTCATCGACGTTTTCCACCAATATTCTGGA
AGGGAGGGAGACAAGCACAAGCTGAAGAAATCCGAACTCAAGGAGCTCATCAACAATGAG
CTTTCCCATTTCTTAGAGGAAATCAAAGAGCAGGAGGTTGTGGACAAAGTCATGGAAACA
CTGGACAATGATGGAGACGGCGAATGTGACTTCCAGGAATTCATGGCCTTTGTTGCCATG
GTTACTACTGCCTGCCACGAGTTCTTTGAACATGAGTGA

# Drug_Target_6_General_Function:
Involved in calcium ion binding

# Drug_Target_6_General_References:
2394738	Allore RJ, Friend WC, O'Hanlon D, Neilson KM, Baumal R, Dunn RJ, Marks A: Cloning and expression of the human S100 beta gene. J Biol Chem. 1990 Sep 15;265(26):15537-43.
4031854	Jensen R, Marshak DR, Anderson C, Lukas TJ, Watterson DM: Characterization of human brain S100 protein fraction: amino acid sequence of S100 beta. J Neurochem. 1985 Sep;45(3):700-5.
6487634	Baudier J, Glasser N, Haglid K, Gerard D: Purification, characterization and ion binding properties of human brain S100b protein. Biochim Biophys Acta. 1984 Oct 23;790(2):164-73.
9519411	Smith SP, Shaw GS: A novel calcium-sensitive switch revealed by the structure of human S100B in the calcium-bound form. Structure. 1998 Feb 15;6(2):211-22.
9925766	Yang Q, O'Hanlon D, Heizmann CW, Marks A: Demonstration of heterodimer formation between S100B and S100A6 in the yeast two-hybrid system and human melanoma. Exp Cell Res. 1999 Feb 1;246(2):501-9.

# Drug_Target_6_HGNC_ID:
HGNC:10500

# Drug_Target_6_HPRD_ID:
01505

# Drug_Target_6_ID:
2132

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
10713

# Drug_Target_6_Name:
Protein S100-B

# Drug_Target_6_Number_of_Residues:
92

# Drug_Target_6_PDB_ID:
1UWO

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00036	efhand
PF01023	S_100

# Drug_Target_6_Protein_Sequence:
>Protein S100-B
MSELEKAMVALIDVFHQYSGREGDKHKLKKSELKELINNELSHFLEEIKEQEVVDKVMET
LDNDGDGECDFQEFMAFVAMVTTACHEFFEHE

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Weakly binds calcium but binds zinc very tightly- distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the binding of both divalent cations, especially affecting high-affinity calcium-binding sites. Binds to and initiates the activation of STK38 by releasing autoinhibitory intramolecular interactions within the kinase

# Drug_Target_6_SwissProt_ID:
P04271

# Drug_Target_6_SwissProt_Name:
S100B_HUMAN

# Drug_Target_6_Synonyms:
S-100 protein beta chain
S-100 protein beta subunit
S100 calcium-binding protein B

# Drug_Target_6_Theoretical_pI:
4.25

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17543955	Hanna RA, Garcia-Diaz BE, Davies PL: Calpastatin simultaneously binds four calpains with different kinetic constants. FEBS Lett. 2007 Jun 26;581(16):2894-8. Epub 2007 May 25.
17570336	De Tullio R, Averna M, Stifanese R, Parr T, Bardsley RG, Pontremoli S, Melloni E: Multiple rat brain calpastatin forms are produced by distinct starting points and alternative splicing of the N-terminal exons. Arch Biochem Biophys. 2007 Sep 1;465(1):148-56. Epub 2007 May 30.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
CAST

# Drug_Target_7_GenBank_ID_Gene:
D16217

# Drug_Target_7_GenBank_ID_Protein:
303599

# Drug_Target_7_GeneCard_ID:
CAST

# Drug_Target_7_Gene_Name:
CAST

# Drug_Target_7_Gene_Sequence:
>2127 bp
ATGAATCCCACAGAAACCAAGGCCATTCCAGTCAGCCAACAGATGGAAGGACCACATCTT
CCTAACAAGAAAAAACACAAAAAACAGGCTGTAAAAACAGAACCTGAGAAGAAGTCACAG
TCAACCAAGCTGTCTGTGGTTCATGAGAAAAAATCCCAAGAAGGAAAGCCAAAAGAACAC
ACAGAGCCAAAAAGCCTACCCAAGCAGGCATCAGATACAGGAAGTAACGATGCTCACAAT
AAAAAAGCAGTTTCCAGATCAGCTGAACAGCAGCCATCAGAGAAATCAACAGAACCAAAG
ACTAAACCACAAGACATGATTTCTGCTGGTGGAGAGAGTGTTGCTGGTATCACTGCAATA
TCTGGCAAGCCGGGTGACAAGAAAAAAGAAAAGAAATCATTAACCCCAGCTGTGCCAGTT
GAATCTAAACCGGATAAACCATCGGGAAAGTCAGGCATGGATGCTGCTTTGGATGACTTA
ATAGATACTTTAGGAGGACCTGAAGAAACTGAAGAAGAAAATACAACGTATACTGGACCA
GAAGTTTCAGATCCAATGAGTTCCACCTACATAGAGGAATTGGGTAAAAGAGAAGTCACA
ATTCCTCCAAAATATAGGGAACTATTGGCTAAAAAGGAAGGGATCACAGGGCCTCCTGCA
GACTCTTCAAAACCCATAGGGCCAGATGATGCTATAGACGCCTTGTCATCTGACTTCACC
TGTGGGTCGCCTACAGCTGCTGGAAAGAAAACTGAAAAAGAGGAATCTACAGAAGTTTTA
AAAGCTCAGTCAGCAGGGACAGTCAGAAGTGCTGCTCCACCCCAAGAGAAGAAAAGAAAG
GTGGAGAAGGATACAATGAGTGATCAAGCACTCGAGGCTCTGTCGGCTTCACTGGGCACC
CGGCAAGCAGAACCTGAGCTCGACCTCCGCTCAATTAAGGAAGTCGATGAGGCAAAAGCT
AAAGAAGAAAAACTAGAGAAGTGTGGTGAGGATGATGAAACAATCCCATCTGAGTACAGA
TTAAAACCAGCCACGGATAAAGATGGAAAACCACTATTGCCAGAGCCTGAAGAAAAACCC
AAGCCTCGGAGTGAATCAGAACTCATTGATGAACTTTCAGAAGATTTTGACCGGTCTGAA
TGTAAAGAGAAACCATCTAAGCCAACTGAAAAGACAGAAGAATCTAAGGCCGCTGCTCCA
GCTCCTGTGTCGGAGGCTGTGTCTCGGACCTCCATGTGTAGTATACAGTCAGCACCCCCT
GAGCCGGCTACCTTGAAGGGCACAGTGCCAGATGATGCTGTAGAAGCCTTGGCTGATAGC
CTGGGGAAAAAGGAAGCAGATCCAGAAGATGGAAAACCTGTGATGGATAAAGTCAAGGAG
AAGGCCAAAGAAGAAGACCGTGAAAAGCTTGGTGAAAAAGAAGAAACAATTCCTCCTGAT
TATAGATTAGAAGAGGTCAAGGATAAAGATGGAAAGCCACTCCTGCCAAAAGAGTCTAAG
GAACAGCTTCCACCCATGAGTGAAGACTTCCTTCTGGATGCTTTGTCTGAGGACTTCTCT
GGTCCACAAAATGCTTCATCTCTTAAATTTGAAGATGCTAAACTTGCTGCTGCCATCTCT
GAAGTGGTTTCCCAAACCCCAGCTTCAACGACCCAAGCTGGAGCCCCACCCCGTGATACC
TCGCAGAGTGACAAAGACCTCGATGATGCCTTGGATAAACTCTCTGACAGTCTAGGACAA
AGGCAGCCTGACCCAGATGAGAACAAACCAATGGGAGATAAAGTAAAGGAAAAAGCTAAA
GCTGAACATAGAGACAAGCTTGGAGAAAGAGATGACACTATCCCACCTGAATACAGACAT
CTCCTGGATGATAATGGACAGGACAAACCAGTGAAGCCACCTACAAAGAAATCAGAGGAT
TCAAAGAAACCTGCAGATGACCAAGACCCCATTGATGCTCTCTCAGGAGATCTGGACAGC
TGTCCCTCCACTACAGAAACCTCACAGAACACAGCAAAGGATAAGTGCAAGAAGGCTGCT
TCCAGCTCCAAAGCACCTAAGAATGGAGGTAAAGCGAAGGATTCAGCAAAGACAACAGAG
GAAACTTCCAAGCCAAAAGATGACTAA

# Drug_Target_7_General_Function:
Cell motility

# Drug_Target_7_General_References:
1569094	Lee WJ, Ma H, Takano E, Yang HQ, Hatanaka M, Maki M: Molecular diversity in amino-terminal domains of human calpastatin by exon skipping. J Biol Chem. 1992 Apr 25;267(12):8437-42.
1995645	Adachi Y, Ishida-Takahashi A, Takahashi C, Takano E, Murachi T, Hatanaka M: Phosphorylation and subcellular distribution of calpastatin in human hematopoietic system cells. J Biol Chem. 1991 Feb 25;266(6):3968-72.
2407243	Uemori T, Shimojo T, Asada K, Asano T, Kimizuka F, Kato I, Maki M, Hatanaka M, Murachi T, Hanzawa H, et al.: Characterization of a functional domain of human calpastatin. Biochem Biophys Res Commun. 1990 Feb 14;166(3):1485-93.
2553724	Maki M, Bagci H, Hamaguchi K, Ueda M, Murachi T, Hatanaka M: Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. J Biol Chem. 1989 Nov 15;264(32):18866-9.
2577276	Asada K, Ishino Y, Shimada M, Shimojo T, Endo M, Kimizuka F, Kato I, Maki M, Hatanaka M, Murachi T: cDNA cloning of human calpastatin: sequence homology among human, pig, and rabbit calpastatins. J Enzyme Inhib. 1989;3(1):49-56.
7706496	Despres N, Talbot G, Plouffe B, Boire G, Menard HA: Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest. 1995 Apr;95(4):1891-6.
7951045	Wang LF, Wei SG, Miao SY, Liu QY, Koide SS: Calpastatin gene in human testis. Biochem Mol Biol Int. 1994 May;33(2):245-51.

# Drug_Target_7_HGNC_ID:
HGNC:1515

# Drug_Target_7_HPRD_ID:
00233

# Drug_Target_7_ID:
1108

# Drug_Target_7_Locus:
5q15

# Drug_Target_7_Molecular_Weight:
76573

# Drug_Target_7_Name:
Calpastatin

# Drug_Target_7_Number_of_Residues:
708

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00748	Calpain_inhib

# Drug_Target_7_Protein_Sequence:
>Calpastatin
MNPTETKAIPVSQQMEGPHLPNKKKHKKQAVKTEPEKKSQSTKLSVVHEKKSQEGKPKEH
TEPKSLPKQASDTGSNDAHNKKAVSRSAEQQPSEKSTEPKTKPQDMISAGGESVAGITAI
SGKPGDKKKEKKSLTPAVPVESKPDKPSGKSGMDAALDDLIDTLGGPEETEEENTTYTGP
EVSDPMSSTYIEELGKREVTIPPKYRELLAKKEGITGPPADSSKPIGPDDAIDALSSDFT
CGSPTAAGKKTEKEESTEVLKAQSAGTVRSAAPPQEKKRKVEKDTMSDQALEALSASLGT
RQAEPELDLRSIKEVDEAKAKEEKLEKCGEDDETIPSEYRLKPATDKDGKPLLPEPEEKP
KPRSESELIDELSEDFDRSECKEKPSKPTEKTEESKAAAPAPVSEAVCRTSMCSIQSAPP
EPATLKGTVPDDAVEALADSLGKKEADPEDGKPVMDKVKEKAKEEDREKLGEKEETIPPD
YRLEEVKDKDGKPLLPKESKEQLPPMSEDFLLDALSEDFSGPQNASSLKFEDAKLAAAIS
EVVSQTPASTTQAGAPPRDTSQSDKDLDDALDKLSDSLGQRQPDPDENKPMEDKVKEKAK
AEHRDKLGERDDTIPPEYRHLLDDNGQDKPVKPPTKKSEDSKKPADDQDPIDALSGDLDS
CPSTTETSQNTAKDKCKKAASSSKAPKNGGKAKDSAKTTEETSKPKDD

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Specific inhibition of calpain (calcium-dependent cysteine protease). Plays a key role in postmortem tenderization of meat and have been proposed to be involved in muscle protein degradation in living tissue

# Drug_Target_7_SwissProt_ID:
P20810

# Drug_Target_7_SwissProt_Name:
ICAL_HUMAN

# Drug_Target_7_Synonyms:
Calpain inhibitor
Sperm BS-17 component

# Drug_Target_7_Theoretical_pI:
4.70

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Secreted protein

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17588949	Chen FH, Herndon ME, Patel N, Hecht JT, Tuan RS, Lawler J: Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. J Biol Chem. 2007 Aug 24;282(34):24591-8. Epub 2007 Jun 22.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
COMP

# Drug_Target_8_GenBank_ID_Gene:
L32137

# Drug_Target_8_GenBank_ID_Protein:
602450

# Drug_Target_8_GeneCard_ID:
COMP

# Drug_Target_8_Gene_Name:
COMP

# Drug_Target_8_Gene_Sequence:
>2274 bp
ATGGTCCCCGACACCGCCTGCGTTCTTCTGCTCACCCTGGCTGCCCTCGGCGCGTCCGGA
CAGGGCCAGAGCCCGTTGGGCTCAGACCTGGGCCCGCAGATGCTTCGGGAACTGCAGGAA
ACCAACGCGGCGCTGCAGGACGTGCGGGACTGGCTGCGGCAGCAGGTCAGGGAGATCACG
TTCCTGAAAAACACGGTGATGGAGTGTGACGCGTGCGGGATGCAGCAGTCAGTACGCACC
GGCCTACCCAGCGTGCGGCCCCTGCTCCACTGCGCGCCCGGCTTCTGCTTCCCCGGCGTG
GCCTGCATCCAGACGGAGAGCGGCGGCCGCTGCGGCCCCTGCCCCGCGGGCTTCACGGGC
AACGGCTCGCACTGCACCGACGTCAACGAGTGCAACGCCCACCCCTGCTTCCCCCGAGTC
CGCTGTATCAACACCAGCCCGGGGTTCCGCTGCGAGGCTTGCCCGCCGGGGTACAGCGGC
CCCACCCACCAGGGCGTGGGGCTGGCTTTCGCCAAGGCCAACAAGCAGGTTTGCACGGAC
ATCAACGAGTGTGAGACCGGGCAACATAACTGCGTCCCCAACTCCGTGTGCATCAACACC
CGGGGCTCCTTCCAGTGCGGCCCGTGCCAGCCCGGCTTCGTGGGCGACCAGGCGTCCGGC
TGCCAGCGCGGCGCACAGCGCTTCTGCCCCGACGGCTCGCCCAGCGAGTGCCACGAGCAT
GCAGACTGCGTCCTAGAGCGCGATGGCTCGCGGTCGTGCGTGTGTCGCGTTGGCTGGGCC
GGCAACGGGATCCTCTGTGGTCGCGACACTGACCTAGACGGCTTCCCGGACGAGAAGCTG
CGCTGCCCGGAGCCGCAGTGCCGTAAGGACAACTGCGTGACTGTGCCCAACTCAGGGCAG
GAGGATGTGGACCGCGATGGCATCGGAGACGCCTGCGATCCGGATGCCGACGGGGACGGG
GTCCCCAATGAAAAGGACAACTGCCCGCTGGTGCGGAACCCAGACCAGCGCAACACGGAC
GAGGACAAGTGGGGCGATGCGTGCGACAACTGCCGGTCCCAGAAGAACGACGACCAAAAG
GACACAGACCAGGACGGCCGGGGCGATGCGTGCGACGACGACATCGACGGCGACCGGATC
CGCAACCAGGCCGACAACTGCCCTAGGGTACCCAACTCAGACCAGAAGGACAGTGATGGC
GATGGTATAGGGGATGCCTGTGACAACTGTCCCCAGAAGAGCAACCCGGATCAGGCGGAT
GTGGACCACGACTTTGTGGGAGATGCTTGTGACAGCGATCAAGACCAGGATGGAGACGGA
CATCAGGACTCTCGGGACAACTGTCCCACGGTGCCTAACAGTGCCCAGGAGGACTCAGAC
CACGATGGCCAGGGTGATGCCTGCGACGACGACGACGACAATGACGGAGTCCCTGACAGT
CGGGACAACTGCCGCCTGGTGCCTAACCCCGGCCAGGAGGACGCGGACAGGGACGGCGTG
GGCGACGTGTGCCAGGACGACTTTGATGCAGACAAGGTGGTAGACAAGATCGACGTGTGT
CCGGAGAACGCTGAAGTCACGCTCACCGACTTCAGGGCCTTCCAGACAGTCGTGCTGGAC
CCGGAGGGTGACGCGCAGATTGACCCCAACTGGGTGGTGCTCAACCAGGGAAGGGAGATC
GTGCAGACAATGAACAGCGACCCAGGCCTGGCTGTGGGTTACACTGCCTTCAATGGCGTG
GACTTCGAGGGCACGTTCCATGTGAACACGGTCACGGATGACGACTATGCGGGCTTCATC
TTTGGCTACCAGGACAGCTCCAGCTTCTACGTGGTCATGTGGAAGCAGATGGAGCAAACG
TATTGGCAGGCGAACCCCTTCCGTGCTGTGGCCGAGCCTGGCATCCAACTCAAGGCTGTG
AAGTCTTCCACAGGCCCCGGGGAACAGCTGCGGAACGCTCTGTGGCATACAGGAGACACA
GAGTCCCAGGTGCGGCTGCTGTGGAAGGACCCGCGAAACGTGGGTTGGAAGGACAAGAAG
TCCTATCGTTGGTTCCTGCAGCACCGGCCCCAAGTGGGCTACATCAGGGTGCGATTCTAT
GAGGGCCCTGAGCTGGTGGCCGACAGCAACGTGGTCTTGGACACAACCATGCGGGGTGGC
CGCCTGGGGGTCTTCTGCTTCTCCCAGGAGAACATCATCTGGGCCAACCTGCGTTACCGC
TGCAATGACACCATCCCAGAGGACTATGAGACCCATCAGCTGCGGCAAGCCTAG

# Drug_Target_8_General_Function:
Amino acid transport and metabolism

# Drug_Target_8_General_References:
11746044	Mabuchi A, Haga N, Ikeda T, Manabe N, Ohashi H, Takatori Y, Nakamura K, Ikegawa S: Novel mutation in exon 18 of the cartilage oligomeric matrix protein gene causes a severe pseudoachondroplasia. Am J Med Genet. 2001 Nov 22;104(2):135-9.
11746045	Unger S, Korkko J, Krakow D, Lachman RS, Rimoin DL, Cohn DH: Double heterozygosity for pseudoachondroplasia and spondyloepiphyseal dysplasia congenita. Am J Med Genet. 2001 Nov 22;104(2):140-6.
7670471	Hecht JT, Nelson LD, Crowder E, Wang Y, Elder FF, Harrison WR, Francomano CA, Prange CK, Lennon GG, Deere M, et al.: Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nat Genet. 1995 Jul;10(3):325-9.
7670472	Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, Mortier GR, Rimoin DL, Lachman RS, Gaines ES, et al.: Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet. 1995 Jul;10(3):330-6.
7713493	Newton G, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkins NA, Lawler J: Characterization of human and mouse cartilage oligomeric matrix protein. Genomics. 1994 Dec;24(3):435-9.
9021009	Ballo R, Briggs MD, Cohn DH, Knowlton RG, Beighton PH, Ramesar RS: Multiple epiphyseal dysplasia, ribbing type: a novel point mutation in the COMP gene in a South African family. Am J Med Genet. 1997 Feb 11;68(4):396-400.
9184241	Susic S, McGrory J, Ahier J, Cole WG: Multiple epiphyseal dysplasia and pseudoachondroplasia due to novel mutations in the calmodulin-like repeats of cartilage oligomeric matrix protein. Clin Genet. 1997 Apr;51(4):219-24.
9452026	Loughlin J, Irven C, Mustafa Z, Briggs MD, Carr A, Lynch SA, Knowlton RG, Cohn DH, Sykes B: Identification of five novel mutations in cartilage oligomeric matrix protein gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Hum Mutat. 1998;Suppl 1:S10-7.
9452063	Susic S, Ahier J, Cole WG: Pseudoachondroplasia due to the substitution of the highly conserved Asp482 by Gly in the seventh calmodulin-like repeat of cartilage oligomeric matrix protein. Hum Mutat. 1998;Suppl 1:S125-7.
9463320	Briggs MD, Mortier GR, Cole WG, King LM, Golik SS, Bonaventure J, Nuytinck L, De Paepe A, Leroy JG, Biesecker L, Lipson M, Wilcox WR, Lachman RS, Rimoin DL, Knowlton RG, Cohn DH: Diverse mutations in the gene for cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum. Am J Hum Genet. 1998 Feb;62(2):311-9.
9921895	Ikegawa S, Ohashi H, Nishimura G, Kim KC, Sannohe A, Kimizuka M, Fukushima Y, Nagai T, Nakamura Y: Novel and recurrent COMP (cartilage oligomeric matrix protein) mutations in pseudoachondroplasia and multiple epiphyseal dysplasia. Hum Genet. 1998 Dec;103(6):633-8.

# Drug_Target_8_HGNC_ID:
HGNC:2227

# Drug_Target_8_HPRD_ID:
02632

# Drug_Target_8_ID:
1089

# Drug_Target_8_Locus:
19p13.1

# Drug_Target_8_Molecular_Weight:
82833

# Drug_Target_8_Name:
Cartilage oligomeric matrix protein

# Drug_Target_8_Number_of_Residues:
757

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00008	EGF
PF02412	TSP_3
PF05735	TSP_C
PF07645	EGF_CA

# Drug_Target_8_Protein_Sequence:
>Cartilage oligomeric matrix protein precursor
MVPDTACVLLLTLAALGASGQGQSPLGSDLGPQMLRELQETNAALQDVRDWLRQQVREIT
FLKNTVMECDACGMQQSVRTGLPSVRPLLHCAPGFCFPGVACIQTESGGRCGPCPAGFTG
NGSHCTDVNECNAHPCFPRVRCINTSPGFRCEACPPGYSGPTHQGVGLAFAKANKQVCTD
INECETGQHNCVPNSVCINTRGSFQCGPCQPGFVGDQASGCQRGAQRFCPDGSPSECHEH
ADCVLERDGSRSCVCRVGWAGNGILCGRDTDLDGFPDEKLRCPEPQCRKDNCVTVPNSGQ
EDVDRDGIGDACDPDADGDGVPNEKDNCPLVRNPDQRNTDEDKWGDACDNCRSQKNDDQK
DTDQDGRGDACDDDIDGDRIRNQADNCPRVPNSDQKDSDGDGIGDACDNCPQKSNPDQAD
VDHDFVGDACDSDQDQDGDGHQDSRDNCPTVPNSAQEDSDHDGQGDACDDDDDNDGVPDS
RDNCRLVPNPGQEDADRDGVGDVCQDDFDADKVVDKIDVCPENAEVTLTDFRAFQTVVLD
PEGDAQIDPNWVVLNQGREIVQTMNSDPGLAVGYTAFNGVDFEGTFHVNTVTDDDYAGFI
FGYQDSSSFYVVMWKQMEQTYWQANPFRAVAEPGIQLKAVKSSTGPGEQLRNALWHTGDT
ESQVRLLWKDPRNVGWKDKKSYRWFLQHRPQVGYIRVRFYEGPELVADSNVVLDTTMRGG
RLGVFCFSQENIIWANLRYRCNDTIPEDYETHQLRQA

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-20

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
P49747

# Drug_Target_8_SwissProt_Name:
COMP_HUMAN

# Drug_Target_8_Synonyms:
COMP
Cartilage oligomeric matrix protein precursor

# Drug_Target_8_Theoretical_pI:
4.14

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17537429	Sosa V, Carbo R, Guarner V: Participation of glucose transporters on atrial natriuretic peptide-induced glucose uptake by adult and neonatal cardiomyocytes under oxygenation and hypoxia. Eur J Pharmacol. 2007 Jul 30;568(1-3):83-8. Epub 2007 Apr 30.
17550897	Zhou Z, Yin J, Dou Z, Tang J, Zhang C, Cao Y: The calponin homology domain of Vav1 associates with calmodulin and is prerequisite to T cell antigen receptor-induced calcium release in Jurkat T lymphocytes. J Biol Chem. 2007 Aug 10;282(32):23737-44. Epub 2007 Jun 5.
17592724	Schallreuter KU, Gibbons NC, Zothner C, Abou Elloof MM, Wood JM: Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: more evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun. 2007 Aug 17;360(1):70-5. Epub 2007 Jun 11.
17595168	Caride AJ, Filoteo AG, Penniston JT, Strehler EE: The plasma membrane Ca2+ pump isoform 4a differs from isoform 4b in the mechanism of calmodulin binding and activation kinetics: implications for Ca2+ signaling. J Biol Chem. 2007 Aug 31;282(35):25640-8. Epub 2007 Jun 26.
17612522	Lo LW, Chen YC, Chen YJ, Wongcharoen W, Lin CI, Chen SA: Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins. Eur J Pharmacol. 2007 Oct 1;571(2-3):197-208. Epub 2007 Jun 13.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
CALM1

# Drug_Target_9_GenBank_ID_Gene:
J04046

# Drug_Target_9_GenBank_ID_Protein:
179888

# Drug_Target_9_GeneCard_ID:
CALM1

# Drug_Target_9_Gene_Name:
CALM1

# Drug_Target_9_Gene_Sequence:
>450 bp
ATGGCTGACCAGCTGACTGAGGAGCAGATTGCAGAGTTCAAGGAGGCCTTCTCCCTCTTT
GACAAGGATGGAGATGGCACTATCACCACCAAGGAGTTGGGGACAGTGATGAGATCCCTG
GGACAGAACCCCACTGAAGCAGAGCTGCAGGATATGATCAATGAGGTGGATGCAGATGGG
AACGGGACCATTGACTTCCCGGAGTTCCTGACCATGATGGCCAGAAAGATGAAGGACACA
GACAGTGAGGAGGAGATCCGAGAGGCGTTCCGTGTCTTTGACAAGGATGGGAATGGCTAC
ATCAGCGCCGCAGAGCTGCGTCACGTAATGACGAACCTGGGGGAGAAGCTGACCGATGAG
GAGGTGGATGAGATGATCAGGGAGGCTGACATCGATGGAGATGGCCAGGTCAATTATGAA
GAGTTTGTACAGATGATGACTGCAAAGTGA

# Drug_Target_9_General_Function:
Involved in calcium ion binding

# Drug_Target_9_General_References:
11807546	Drum CL, Yan SZ, Bard J, Shen YQ, Lu D, Soelaiman S, Grabarek Z, Bohm A, Tang WJ: Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature. 2002 Jan 24;415(6870):396-402.
12508121	Heilig R, Eckenberg R, Petit JL, Fonknechten N, Da Silva C, Cattolico L, Levy M, Barbe V, de Berardinis V, Ureta-Vidal A, Pelletier E, Vico V, Anthouard V, Rowen L, Madan A, Qin S, Sun H, Du H, Pepin K, Artiguenave F, Robert C, Cruaud C, Bruls T, Jaillon O, Friedlander L, Samson G, Brottier P, Cure S, Segurens B, Aniere F, Samain S, Crespeau H, Abbasi N, Aiach N, Boscus D, Dickhoff R, Dors M, Dubois I, Friedman C, Gouyvenoux M, James R, Madan A, Mairey-Estrada B, Mangenot S, Martins N, Menard M, Oztas S, Ratcliffe A, Shaffer T, Trask B, Vacherie B, Bellemere C, Belser C, Besnard-Gonnet M, Bartol-Mavel D, Boutard M, Briez-Silla S, Combette S, Dufosse-Laurent V, Ferron C, Lechaplais C, Louesse C, Muselet D, Magdelenat G, Pateau E, Petit E, Sirvain-Trukniewicz P, Trybou A, Vega-Czarny N, Bataille E, Bluet E, Bordelais I, Dubois M, Dumont C, Guerin T, Haffray S, Hammadi R, Muanga J, Pellouin V, Robert D, Wunderle E, Gauguet G, Roy A, Sainte-Marthe L, Verdier J, Verdier-Discala C, Hillier L, Fulton L, McPherson J, Matsuda F, Wilson R, Scarpelli C, Gyapay G, Wincker P, Saurin W, Quetier F, Waterston R, Hood L, Weissenbach J: The DNA sequence and analysis of human chromosome 14. Nature. 2003 Feb 6;421(6923):601-7. Epub 2003 Jan 1.
2223880	Koller M, Schnyder B, Strehler EE: Structural organization of the human CaMIII calmodulin gene. Biochim Biophys Acta. 1990 Oct 23;1087(2):180-9.
2445749	SenGupta B, Friedberg F, Detera-Wadleigh SD: Molecular analysis of human and rat calmodulin complementary DNA clones. Evidence for additional active genes in these species. J Biol Chem. 1987 Dec 5;262(34):16663-70.
3182832	Fischer R, Koller M, Flura M, Mathews S, Strehler-Page MA, Krebs J, Penniston JT, Carafoli E, Strehler EE: Multiple divergent mRNAs code for a single human calmodulin. J Biol Chem. 1988 Nov 15;263(32):17055-62.
6385987	Wawrzynczak EJ, Perham RN: Isolation and nucleotide sequence of a cDNA encoding human calmodulin. Biochem Int. 1984 Aug;9(2):177-85.
7093203	Sasagawa T, Ericsson LH, Walsh KA, Schreiber WE, Fischer EH, Titani K: Complete amino acid sequence of human brain calmodulin. Biochemistry. 1982 May 11;21(10):2565-9.
7925473	Rhyner JA, Ottiger M, Wicki R, Greenwood TM, Strehler EE: Structure of the human CALM1 calmodulin gene and identification of two CALM1-related pseudogenes CALM1P1 and CALM1P2. Eur J Biochem. 1994 Oct 1;225(1):71-82.
9681195	Toutenhoofd SL, Foletti D, Wicki R, Rhyner JA, Garcia F, Tolon R, Strehler EE: Characterization of the human CALM2 calmodulin gene and comparison of the transcriptional activity of CALM1, CALM2 and CALM3. Cell Calcium. 1998 May;23(5):323-38.

# Drug_Target_9_HGNC_ID:
HGNC:1442

# Drug_Target_9_HPRD_ID:
00243

# Drug_Target_9_ID:
465

# Drug_Target_9_Locus:
14q24-q31

# Drug_Target_9_Molecular_Weight:
16707

# Drug_Target_9_Name:
Calmodulin

# Drug_Target_9_Number_of_Residues:
148

# Drug_Target_9_PDB_ID:
1IQ5

# Drug_Target_9_Pathway:
Acebutolol Pathway	SMP00296
Alprenolol Pathway	SMP00297
Amlodipine Pathway	SMP00376
Atenolol Pathway	SMP00298
Benazepril Pathway	SMP00145
Betaxolol Pathway	SMP00299
Bisoprolol Pathway	SMP00300
Captopril Pathway	SMP00146
Carvedilol Pathway	SMP00367
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Enalapril Pathway	SMP00148
Esmolol Pathway	SMP00301
Felodipine Pathway	SMP00377
Fosinopril Pathway	SMP00149
Isradipine Pathway	SMP00378
Labetalol Pathway	SMP00368
Lisinopril Pathway	SMP00150
Metoprolol Pathway	SMP00302
Moexipril Pathway	SMP00151
Nadolol Pathway	SMP00303
Nebivolol Pathway	SMP00366
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Oxprenolol Pathway	SMP00304
Penbutolol Pathway	SMP00305
Perindopril Pathway	SMP00152
Pindolol Pathway	SMP00306
Propranolol Pathway	SMP00307
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_9_Pfam_Domain_Function:
PF00036	efhand

# Drug_Target_9_Protein_Sequence:
>Calmodulin
ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGN
GTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEE
VDEMIREADIDGDGQVNYEEFVQMMTAK

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Calmodulin mediates the control of a large number of enzymes and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases

# Drug_Target_9_SwissProt_ID:
P62158

# Drug_Target_9_SwissProt_Name:
CALM_HUMAN

# Drug_Target_9_Synonyms:
CaM

# Drug_Target_9_Theoretical_pI:
3.84

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB01373
